The US Medicare agency will expand its competitive bidding program for durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) to include insulin pumps, and will add 10 new competitive bidding areas for continuous positive airway pressure (CPAP) devices. Many device suppliers, as well as Trump’s HHS Secretary-nominee Tom Price, oppose the bidding program.
CMS is expanding its durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) competitive bidding program in 2019 to add insulin pumps and supplies to the list of DMEPOS covered, and to add 10 new competitive bidding areas for the program for continuous positive airway pressure (CPAP) devices, the agency announced Jan. 31.
Mandated by the Medicare Prescription Drug, Improvement and Modernization Act of 2013, the competitive bidding program sets the amount Medicare...
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
